Am I right in thinking that strategically this increases the pressure on existing SOC treatments to do similar combination trials / agreements with Imugene?
It makes me think the business side of IMU is almost as smart as the medical tech side of Imugene.
Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS, page-18
-
- There are more pages in this discussion • 329 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |